These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19131041)

  • 1. Toxic effects of dopamine metabolism in Parkinson's disease.
    Hattoria N; Wanga M; Taka H; Fujimura T; Yoritaka A; Kubo S; Mochizuki H
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S35-8. PubMed ID: 19131041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
    Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
    Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathogenesis of Parkinson's disease.
    Gandhi S; Wood NW
    Hum Mol Genet; 2005 Sep; 14(18):2749-55. PubMed ID: 16126732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein and Parkinson's disease: a proteomic view.
    Fasano M; Lopiano L
    Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress.
    Mytilineou C; Walker RH; JnoBaptiste R; Olanow CW
    J Pharmacol Exp Ther; 2003 Feb; 304(2):792-800. PubMed ID: 12538835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
    Maguire-Zeiss KA; Short DW; Federoff HJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Free radicals and ailing proteins--the culprits behind Parkinson disease?].
    Smith R; Lotharius J; Brundin P
    Lakartidningen; 2003 Apr; 100(15):1324-6, 1329-30. PubMed ID: 12739402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2012 Nov; 53(9):1791-806. PubMed ID: 22967820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective and toxic roles of dopamine in Parkinson's disease.
    Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
    J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of JNK pathway in familial Parkinson's disease].
    Jankowski M
    Postepy Biochem; 2007; 53(3):297-303. PubMed ID: 18399358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
    Sass MB; Lorenz AN; Green RL; Coleman RA
    J Neurosci Methods; 2009 Apr; 178(2):366-77. PubMed ID: 19136028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease.
    Witt SN; Flower TR
    FEMS Yeast Res; 2006 Dec; 6(8):1107-16. PubMed ID: 17156009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease. Dopamine may sustain toxic protein.
    Couzin J
    Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
    [No Abstract]   [Full Text] [Related]  

  • 17. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease.
    Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):271-82. PubMed ID: 15580550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
    Hald A; Lotharius J
    Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis.
    Henchcliffe C; Beal MF
    Nat Clin Pract Neurol; 2008 Nov; 4(11):600-9. PubMed ID: 18978800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.